Index -
P/E -
EPS (ttm) -8.33
Insider Own 6.45%
Shs Outstand 82.31M
Perf Week -5.70%
Market Cap 3.50B
Forward P/E -
EPS next Y -4.99
Insider Trans -1.83%
Shs Float 77.02M
Perf Month -9.43%
Income -606.64M
PEG -
EPS next Q -1.73
Inst Own 104.07%
Short Float 5.69%
Perf Quarter -5.21%
Sales 434.25M
P/S 8.07
EPS this Y 22.64%
Inst Trans -3.16%
Short Ratio 6.30
Perf Half Y 29.66%
Book/sh 3.35
P/B 12.71
EPS next Y 21.85%
ROA -39.80%
Short Interest 4.38M
Perf Year -2.59%
Cash/sh 7.03
P/C 6.05
EPS next 5Y 8.90%
ROE -193.23%
52W Range 31.52 - 54.98
Perf YTD -11.04%
Dividend Est. -
P/FCF -
EPS past 5Y -15.75%
ROI -51.92%
52W High -22.63%
Beta 0.67
Dividend TTM -
Quick Ratio 2.49
Sales past 5Y 63.06%
Gross Margin 88.54%
52W Low 34.96%
ATR (14) 2.02
Dividend Ex-Date -
Current Ratio 2.61
EPS Y/Y TTM 17.65%
Oper. Margin -131.08%
RSI (14) 38.83
Volatility 3.67% 4.74%
Employees 1276
Debt/Eq 3.39
Sales Y/Y TTM 19.52%
Profit Margin -139.70%
Recom 1.29
Target Price 89.52
Option/Short Yes / Yes
LT Debt/Eq 3.24
EPS Q/Q 29.83%
Payout -
Rel Volume 1.03
Prev Close 44.02
Sales Surprise 6.71%
EPS Surprise 10.98%
Sales Q/Q 23.27%
Earnings May 02 AMC
Avg Volume 695.19K
Price 42.54
SMA20 -7.65%
SMA50 -10.91%
SMA200 0.98%
Trades
Volume 714,667
Change -3.36%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-24 Initiated
RBC Capital Mkts
Outperform
$77
Dec-08-23 Initiated
Wells Fargo
Overweight
$72
Jun-14-23 Resumed
Credit Suisse
Outperform
$96
Jun-06-23 Upgrade
Evercore ISI
In-line → Outperform
$60 → $80
Apr-26-23 Initiated
Cantor Fitzgerald
Overweight
$114
Jan-18-23 Resumed
Canaccord Genuity
Buy
$90
Dec-30-22 Resumed
H.C. Wainwright
Buy
$82
Nov-03-22 Upgrade
Robert W. Baird
Neutral → Outperform
$50
Oct-13-22 Upgrade
Guggenheim
Neutral → Buy
$50
Aug-01-22 Downgrade
Evercore ISI
Outperform → In-line
$95 → $60
Mar-16-22 Upgrade
Credit Suisse
Neutral → Outperform
$99 → $105
Feb-11-22 Upgrade
JP Morgan
Neutral → Overweight
$132
Sep-30-21 Initiated
H.C. Wainwright
Buy
$106
Aug-19-21 Initiated
UBS
Sell
$73
Jul-15-21 Initiated
Guggenheim
Neutral
Jun-29-21 Upgrade
BofA Securities
Neutral → Buy
$162
Jun-04-21 Resumed
Robert W. Baird
Neutral
$109
May-06-21 Upgrade
Evercore ISI
In-line → Outperform
$144
May-06-21 Upgrade
Citigroup
Neutral → Buy
$160 → $151
Apr-26-21 Resumed
Credit Suisse
Neutral
$99
Show Previous Ratings
Today 04:00PM
08:00AM
Apr-25-24 04:30PM
Apr-19-24 04:30PM
Apr-16-24 11:33AM
07:30AM
Loading…
Apr-15-24 07:30AM
07:00AM
Apr-12-24 04:22PM
08:00AM
Mar-22-24 04:00PM
Mar-20-24 08:11AM
Mar-12-24 05:00PM
Mar-11-24 03:00PM
Mar-08-24 09:38AM
Feb-27-24 04:30PM
04:05PM
Loading…
Feb-23-24 04:05PM
Feb-16-24 10:43AM
10:35AM
(Thomson Reuters StreetEvents)
07:53AM
Feb-15-24 04:15PM
(Associated Press Finance)
04:01PM
Feb-13-24 01:36PM
Feb-08-24 04:00PM
Feb-06-24 08:00AM
Feb-05-24 04:05PM
Jan-25-24 04:05PM
Jan-19-24 04:00PM
Jan-18-24 02:41PM
(Investor's Business Daily)
Jan-09-24 06:20PM
Jan-08-24 12:18PM
07:00AM
Loading…
07:00AM
Jan-07-24 11:00AM
Jan-04-24 08:12AM
08:00AM
Jan-03-24 08:00AM
Jan-02-24 04:05PM
Dec-27-23 06:41PM
Dec-21-23 05:21PM
(The Wall Street Journal)
04:30PM
Dec-18-23 09:29AM
08:00AM
Dec-15-23 10:18AM
Nov-20-23 04:30PM
Nov-17-23 04:30PM
Nov-07-23 05:00PM
Nov-04-23 01:12PM
12:16PM
Nov-03-23 11:43AM
Nov-02-23 06:26PM
04:36PM
(Associated Press Finance)
04:05PM
Oct-26-23 04:05PM
Oct-25-23 06:17AM
Oct-23-23 04:01PM
04:01PM
Oct-20-23 04:00PM
Oct-18-23 09:16PM
Oct-17-23 04:02PM
Oct-16-23 08:00AM
Oct-14-23 04:30PM
Oct-12-23 05:00PM
Oct-09-23 08:00AM
Oct-05-23 08:00AM
Sep-25-23 05:13PM
Sep-20-23 05:00PM
Sep-07-23 12:36PM
Aug-31-23 09:00AM
Aug-18-23 05:00PM
Aug-12-23 11:05AM
Aug-11-23 11:14AM
(American City Business Journals)
Aug-10-23 06:27PM
Aug-08-23 07:11AM
06:20AM
Aug-04-23 08:34AM
(Thomson Reuters StreetEvents) -8.79%
08:12AM
Aug-03-23 04:09PM
04:00PM
Jul-31-23 08:00AM
Jul-27-23 05:00PM
05:05AM
(American City Business Journals)
Jul-18-23 05:00PM
Jul-13-23 03:00PM
Jul-12-23 08:00AM
Jul-07-23 07:46AM
Jul-06-23 08:00AM
Jun-28-23 11:06AM
Jun-21-23 08:00AM
Jun-20-23 05:00PM
Jun-09-23 10:55AM
Jun-07-23 05:00PM
03:21AM
Jun-05-23 04:00PM
May-24-23 06:39AM
May-19-23 08:30AM
May-18-23 05:00PM
11:15AM
May-17-23 08:00AM
May-15-23 02:43PM
(Investor's Business Daily)
May-08-23 04:02PM
May-05-23 04:01PM
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Crombez Eric EVP and Chief Medical Officer Apr 18 '24 Sale 44.10 142 6,262 48,785 Apr 19 04:35 PM Kassberg Thomas Richard CBO & EVP Mar 11 '24 Sale 49.93 11,509 574,644 252,823 Mar 12 01:41 PM Fust Matthew K Director Mar 07 '24 Sale 50.88 12,195 620,443 14,860 Mar 11 12:54 PM Harris Erik EVP & Chief Commercial Officer Mar 01 '24 Sale 53.76 4,768 256,328 67,163 Mar 05 08:08 PM Pinion John Richard See Remarks Mar 01 '24 Sale 53.76 4,173 224,340 89,268 Mar 05 08:15 PM Parschauer Karah Herdman EVP and Chief Legal Officer Mar 01 '24 Sale 53.76 3,756 201,923 67,340 Mar 05 08:22 PM Crombez Eric EVP and Chief Medical Officer Mar 01 '24 Sale 53.76 1,238 66,555 48,927 Mar 05 08:10 PM Kassberg Thomas Richard CBO & EVP Mar 01 '24 Sale 53.76 1,011 54,351 264,332 Mar 05 08:19 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Mar 01 '24 Sale 53.76 341 18,332 41,380 Mar 05 08:13 PM KAKKIS EMIL D President & CEO Feb 07 '24 Sale 45.00 30,000 1,350,000 539,770 Feb 08 03:49 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Jan 02 '24 Option Exercise 21.00 3,000 63,000 27,892 Jan 02 04:06 PM KAKKIS EMIL D President & CEO Dec 29 '23 Sale 47.87 30,000 1,436,100 569,770 Jan 02 04:07 PM Kassberg Thomas Richard CBO & EVP Oct 23 '23 Option Exercise 6.86 39,878 273,563 286,738 Oct 24 05:22 PM Kassberg Thomas Richard CBO & EVP Oct 23 '23 Sale 32.78 39,878 1,307,201 246,860 Oct 24 05:22 PM KAKKIS EMIL D President & CEO Oct 19 '23 Option Exercise 6.86 47,853 328,272 647,029 Oct 23 05:14 PM KAKKIS EMIL D President & CEO Oct 19 '23 Sale 33.52 47,853 1,604,033 599,743 Oct 23 05:14 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 07 '23 Option Exercise 21.00 2,000 42,000 25,777 Sep 11 01:52 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 07 '23 Sale 40.80 2,163 88,249 23,614 Sep 11 01:52 PM Harris Erik EVP & Chief Commercial Officer Sep 05 '23 Sale 37.96 6,000 227,760 51,281 Sep 06 05:51 PM Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 01 '23 Sale 37.15 970 36,032 23,777 Sep 06 05:50 PM Sanders Corazon (Corsee) D. Director Jun 30 '23 Sale 46.76 585 27,355 8,985 Jun 30 02:34 PM Harris Erik EVP & Chief Commercial Officer Jun 19 '23 Sale 48.20 305 14,701 57,281 Jun 21 06:17 PM Sanders Corazon (Corsee) D. Director Jun 08 '23 Sale 51.65 1,485 76,700 9,570 Jun 09 02:31 PM Pinion John Richard See Remarks May 18 '23 Sale 50.00 2,012 100,600 74,744 May 19 01:54 PM Huizenga Theodore Alan SVP, Chief Accounting Officer May 09 '23 Option Exercise 21.00 3,000 63,000 30,747 May 10 08:09 PM Parschauer Karah Herdman EVP and Chief Legal Officer May 04 '23 Sale 45.00 4,378 197,010 51,982 May 05 02:16 PM
Index RUT
P/E -
EPS (ttm) -1.08
Insider Own 21.18%
Shs Outstand 57.82M
Perf Week 0.60%
Market Cap 723.86M
Forward P/E 72.95
EPS next Y 0.16
Insider Trans -1.82%
Shs Float 48.47M
Perf Month -14.43%
Income -61.69M
PEG -
EPS next Q -0.15
Inst Own 75.11%
Short Float 9.57%
Perf Quarter -9.25%
Sales 202.09M
P/S 3.58
EPS this Y 44.61%
Inst Trans 0.64%
Short Ratio 7.99
Perf Half Y 52.66%
Book/sh -0.36
P/B -
EPS next Y 146.54%
ROA -33.62%
Short Interest 4.64M
Perf Year 34.67%
Cash/sh 1.02
P/C 11.52
EPS next 5Y 16.50%
ROE -1279.29%
52W Range 7.07 - 15.43
Perf YTD 11.78%
Dividend Est. -
P/FCF -
EPS past 5Y 10.81%
ROI -59.04%
52W High -23.73%
Beta 1.48
Dividend TTM -
Quick Ratio 2.10
Sales past 5Y 44.65%
Gross Margin 67.00%
52W Low 66.48%
ATR (14) 0.43
Dividend Ex-Date -
Current Ratio 2.33
EPS Y/Y TTM 18.34%
Oper. Margin -17.87%
RSI (14) 34.95
Volatility 3.16% 3.30%
Employees 273
Debt/Eq -
Sales Y/Y TTM 35.98%
Profit Margin -30.52%
Recom 1.12
Target Price 22.29
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 11.67%
Payout -
Rel Volume 0.56
Prev Close 11.71
Sales Surprise 1.34%
EPS Surprise -0.65%
Sales Q/Q 39.76%
Earnings May 07 AMC
Avg Volume 580.63K
Price 11.77
SMA20 -4.44%
SMA50 -11.81%
SMA200 10.89%
Trades
Volume 323,303
Change 0.51%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-29-24 Upgrade
Barclays
Equal Weight → Overweight
$10 → $16
Jun-23-22 Initiated
Needham
Buy
$18
May-12-22 Upgrade
Barclays
Underweight → Equal Weight
$8 → $10
Jan-20-22 Upgrade
Truist
Hold → Buy
$11
May-06-21 Upgrade
Mizuho
Neutral → Buy
$15
Apr-08-21 Reiterated
H.C. Wainwright
Buy
$20 → $22
Feb-24-21 Downgrade
Truist
Buy → Hold
$12
Jul-07-20 Downgrade
Mizuho
Buy → Neutral
$8 → $3
Feb-06-20 Resumed
Mizuho
Buy
Nov-26-19 Initiated
SVB Leerink
Outperform
$25
Sep-05-19 Resumed
Mizuho
Buy
$30
Jun-28-19 Initiated
Wells Fargo
Market Perform
$16
Jun-11-19 Initiated
Barclays
Underweight
$13
Mar-20-19 Initiated
SunTrust
Buy
$30
Feb-14-19 Initiated
H.C. Wainwright
Buy
$37
Jan-29-19 Initiated
Stifel
Buy
$27
Show Previous Ratings
Apr-23-24 04:30PM
Apr-21-24 10:39AM
Apr-17-24 04:05PM
Apr-12-24 04:05PM
Mar-26-24 08:00AM
07:04AM
Loading…
Mar-14-24 07:04AM
Mar-13-24 09:55AM
Mar-11-24 07:00AM
Mar-08-24 04:05PM
03:24PM
12:30PM
(Thomson Reuters StreetEvents)
Mar-07-24 10:34PM
09:53PM
04:05PM
Mar-04-24 08:28PM
08:30AM
Loading…
Mar-01-24 08:30AM
Feb-27-24 08:30AM
Feb-22-24 04:30PM
Feb-09-24 04:05PM
Feb-02-24 09:10PM
Jan-16-24 05:28PM
Jan-12-24 04:23PM
Jan-09-24 06:21PM
Jan-04-24 04:05PM
Dec-20-23 08:00AM
Dec-08-23 04:30PM
Nov-13-23 09:08AM
Nov-10-23 05:16PM
Nov-07-23 04:16PM
Nov-06-23 08:45AM
08:45AM
Loading…
Nov-01-23 08:45AM
Oct-25-23 08:45AM
08:45AM
Oct-08-23 06:41PM
Sep-29-23 04:05PM
Sep-13-23 04:10PM
Sep-09-23 01:03PM
Sep-03-23 05:29AM
Aug-29-23 08:45AM
Aug-27-23 07:20PM
Aug-23-23 06:53PM
Aug-21-23 08:45AM
Aug-08-23 09:15AM
08:45AM
Aug-02-23 05:45PM
04:05PM
Jul-27-23 11:42AM
08:45AM
Jul-26-23 10:02AM
08:45AM
Jul-19-23 08:45AM
Jul-15-23 07:30AM
Jun-29-23 09:00AM
Jun-22-23 08:45AM
Jun-08-23 04:05PM
Jun-02-23 06:38AM
May-16-23 01:44PM
May-09-23 05:25PM
04:01PM
04:01PM
May-05-23 01:37PM
Apr-17-23 11:05AM
Apr-04-23 10:39AM
Mar-11-23 06:38AM
Mar-09-23 10:12AM
(Thomson Reuters StreetEvents)
Mar-08-23 05:35PM
04:05PM
Feb-28-23 08:45AM
Feb-27-23 08:45AM
Feb-22-23 08:45AM
Feb-10-23 11:07AM
Jan-31-23 08:45AM
Jan-30-23 12:02PM
07:09AM
Jan-28-23 08:00AM
Jan-23-23 09:00AM
08:00AM
Jan-20-23 01:54PM
Jan-19-23 01:15PM
Jan-18-23 08:45AM
Jan-03-23 10:03AM
Dec-08-22 08:45AM
Dec-07-22 10:00AM
09:17AM
Nov-10-22 05:57AM
Nov-08-22 06:25PM
04:05PM
Nov-02-22 08:45AM
Oct-25-22 08:45AM
Oct-04-22 08:20AM
Sep-21-22 08:45AM
Sep-20-22 09:03AM
Sep-18-22 07:30AM
Sep-09-22 02:30PM
Sep-06-22 04:05PM
Aug-30-22 08:15AM
Aug-29-22 05:45AM
Aug-24-22 08:14AM
Aug-22-22 08:37AM
Aug-02-22 09:25AM
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MOATAZEDI DAVID See Remarks Mar 27 '24 Sale 13.86 6,236 86,431 689,614 Mar 29 07:08 PM MOATAZEDI DAVID See Remarks Mar 19 '24 Sale 13.92 96,566 1,344,604 695,850 Mar 21 06:08 PM Avelar Rui See Remarks Mar 19 '24 Sale 13.92 27,603 384,350 372,288 Mar 21 06:09 PM Beaver Sandra Chief Financial Officer Mar 19 '24 Sale 13.92 5,672 78,978 154,201 Mar 21 06:09 PM MOATAZEDI DAVID See Remarks Feb 22 '24 Sale 13.08 7,706 100,804 792,416 Feb 23 08:27 PM Beaver Sandra Chief Financial Officer Feb 22 '24 Sale 13.08 1,821 23,821 159,873 Feb 23 08:27 PM Avelar Rui See Remarks Feb 22 '24 Sale 13.08 1,821 23,821 399,891 Feb 23 08:27 PM Parschauer Karah Herdman Director Jan 30 '24 Sale 13.14 11,931 156,733 31,243 Feb 02 04:57 PM MOATAZEDI DAVID See Remarks Dec 08 '23 Sale 9.73 31,300 304,505 603,944 Dec 08 06:15 PM MOATAZEDI DAVID See Remarks Dec 06 '23 Sale 10.09 51,348 517,891 635,244 Dec 08 06:15 PM Medytox Inc. Former 10% Owner Oct 16 '23 Sale 7.50 1,690,663 12,679,972 3,381,326 Oct 18 04:21 PM Beaver Sandra Chief Financial Officer Sep 06 '23 Sale 9.70 3,178 30,827 113,368 Sep 08 08:54 PM MOATAZEDI DAVID See Remarks Aug 16 '23 Sale 10.27 14,778 151,770 686,592 Aug 16 08:25 PM Beaver Sandra Chief Financial Officer Aug 16 '23 Sale 10.27 2,211 22,707 116,546 Aug 16 08:25 PM Avelar Rui See Remarks Aug 16 '23 Sale 10.27 2,211 22,707 353,386 Aug 16 08:25 PM Malik Vikram Director Aug 15 '23 Buy 7.41 174,967 1,296,505 275,550 Aug 15 04:34 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite